Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05286957 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC

Study acronym: Seagull
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 17, 2023 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Song Zhao to The First Affiliated Hospital of Zhengzhou Universityv2 Show 12 more changesShow less
    • Trial status: Not Yet Recruiting to Recruiting
    • Enrollment target: 30 to 60
    • Primary completion date: Jun 1, 2023 to Jun 1, 2026
    • Start date changed from estimate of Mar 20, 2022 to Jun 20, 2022
    • Primary endpoint revised
    • Study completion date: Jun 1, 2026 to Jun 1, 2027
    • Interventions: Tislelizumab monotherapy (Drug) to adjuvant chemotherapy for MRD- patients (Drug), adjuvant tislelizumab and chemotherapy for MRD+ patients (Drug), adjuvant tislelizumab and…
    • Eligibility criteria shortened, about 26 words
    • Secondary endpoint revised
    • Study description expanded, about 31 words
    • Study arms: 1 to 2
    • Study title shortened, about 2 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Seagull is a phase Ⅱ study designed to investigate the efficacy and safety of MRD-guided adjuvant tislelizumab and chemotherapy vs adjuvant tislelizumab and chemotherapy in patients with resectable NSCLC
Trial Details
NCT Number NCT05286957
Lead Sponsor The First Affiliated Hospital of Zhengzhou University
Collaborators: BeiGene
Conditions
(from sponsor)		 NSCLC
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov